4030 Fabian Way
About Immune-Onc Therapeutics
Immune-Onc Therapeutics (“Immune-Onc”) is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.
Founders: Guo Liang Yu and Charlene Liao
7 articles with Immune-Onc Therapeutics
Immune-Onc Therapeutics (“Immune-Onc”), a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients, today announced the appointments of Dr. Adrian Jubb as Chief Medical Officer and of Dr. An Song as Senior Vice President of Development Sciences.
Immune-Onc Therapeutics launched in September 2016 and is headquartered in Palo Alto, California.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Immune-Onc Therapeutics Announces Partnership With University of Texas To Develop Novel Cancer Immunotherapy
Immune-Onc Therapeutics Announces Licensing And Collaboration With Albert Einstein College of Medicine And Memorial Sloan-Kettering Cancer Center To Develop Novel Cancer Immunotherapy